StockNow
Log in
U.S. MarketsIMPORTANT

Abbott Laboratories (ABT) Q2 2026 (USD): Adj. EPS 1.31 (exp. 1.28), Revenue 12.6bln (exp. 12.52bln). Raises FY adj. EPS view 5.45-5.60 (exp. 5.49, prev. 5.38-5.58), Reaffirms sales growth view 6.5-7.5%.

StockNow breaking-news AI analysis

Abbott reported Q2 2026 results exceeding estimates and raised its full-year EPS guidance while maintaining its sales growth forecast, indicating sustained momentum for the fiscal year.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

Geopolitics

US Treasury official says the latest removal of sanctions on Iran is not indicative of any shift in US policy toward the Government of Iran, Fox's Heinrich reports

Fed

Fed's Kashkari (2026 voter, Hawkish dissenter) says now is the time to start slowly moving up rates, but not calling for dramatic rate hikes